CTKB offering history
Every offering-related filing in Cytek Biosciences, Inc.’s recent SEC record — registrations (announced capacity) kept separate from pricing documents (executed sales). Reviewed 452 filings back to Nov 10, 2020.
| Date | Filing | What it means | |
|---|---|---|---|
| Aug 26, 2022 | S-3ASR → | REGISTERED | Automatic shelf registration — effective immediately (large filers) |
| Jul 23, 2021 | 424B4 → | EXECUTED | Final prospectus — offering priced (typical for IPOs and marketed share deals) |
| Jul 22, 2021 | EFFECT → | EFFECTIVE | SEC declared a registration effective — selling can begin |
| Jul 19, 2021 | S-1/A → | REGISTERED | S-1/A registration — capacity to sell shares, not a sale yet |
| Jul 14, 2021 | S-1/A → | REGISTERED | S-1/A registration — capacity to sell shares, not a sale yet |
| Jul 2, 2021 | S-1 → | REGISTERED | S-1 registration — capacity to sell shares, not a sale yet |
Two honest limits. (1) A 424B takedown can price shares or notes— EDGAR’s metadata doesn’t say which, so open the document: large investment-grade filers use these mostly for bond deals (no dilution), small-caps mostly for shares. (2) At-the-market (ATM) programs sell shares gradually and individual sales are not separately filed — the visible footprint is the enabling shelf and its 424B5; actual ATM share counts surface later in the 10-Q/10-K share count. Educational information from public filings, not investment advice.
CTKB offering FAQ
When did CTKB last execute an offering?
Per SEC filings, Cytek Biosciences, Inc.'s most recent priced offering document is a 424B4 filed 2021-07-23. Note a 424B takedown can price shares or notes (debt) — the linked document says which.
When did CTKB last announce or register an offering?
The most recent registration is a S-3ASR filed 2022-08-26. A registration is capacity to sell shares — not a sale.
Does an offering always mean dilution?
Registered direct offerings and shelf takedowns issue new shares and dilute existing holders. Resale registrations (424B3/B7) let existing holders sell and do not create new shares. Secondary sales by insiders also do not dilute. Each row here is labeled with what it is.